disorders

Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing

NEW YORK--(BUSINESS WIRE)--In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on…

2 weeks ago

Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions

Phase 1 data evaluating VRB-101, Verdiva Bio’s cAMP-biased oral GLP-1RA, provides proof of concept for potential once-weekly oral administration. Preclinical…

1 month ago

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

June 19, 2025 01:00 ET  | Source: Addex Therapeutics Strong cash position of CHF2.8 million at end of Q1 2025GABAB…

1 month ago

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025

June 18, 2025 01:00 ET  | Source: Addex Therapeutics Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a…

1 month ago

KFSHRC First in the Middle East to Implant AI-Powered Brain-Sensing Device for Treating Neurological Disorders

RIYADH, Saudi Arabia, June 11, 2025 (GLOBE NEWSWIRE) -- In a landmark medical achievement, King Faisal Specialist Hospital & Research…

1 month ago

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

NEW HAVEN, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., a pioneering techbio company working to decode the human…

2 months ago

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

June 06, 2025 16:01 ET  | Source: Keros Therapeutics, Inc. LEXINGTON, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics,…

2 months ago

Addex Convenes Annual General Meeting 2025

June 03, 2025 01:00 ET  | Source: Addex Therapeutics Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and…

2 months ago